As reported by Bionity.com, PL BioScience GmbH has announced the signing of a Letter of Intent (LOI) with Korean biotech company DewCell Biotherapeutics for the supply of artificial platelet raw material. The new technology, which will be produced in Germany with raw material from DewCell, offers a scalable, safe and animal-free alternative to Fetal Bovine Serum (FBS) and conventional HPL. PL BioScience recently submitted a patent application for the process.

DewCell is the first company to produce artificial platelets from stem cells in a reactor. Under the terms of the agreement, DewCell will supply batches of artificial platelets for PL BioScience's artificial HPL solution, strengthening the company's ability to meet the growing global demand for high-quality, animal-free cell culture media.

Sources and further information:
https://www.pl-bioscience.com/2025/05/08/artificial-human-platelet-lysate-solution/
https://www.bionity.com/de/